Sign In
Buy ASMB
$25.55
+0.330 (+1.31%)
At Close: Jul 24, 2026
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infectio
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
10:50am, Monday, 05'th May 2025
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
10:35am, Tuesday, 08'th Apr 2025
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 26'th Mar 2025
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
04:05pm, Thursday, 20'th Mar 2025
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
08:00am, Wednesday, 26'th Feb 2025
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dos
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
10:47am, Monday, 16'th Sep 2024
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
08:00am, Wednesday, 22'nd May 2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at t
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
04:05pm, Wednesday, 08'th May 2024
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
04:05pm, Thursday, 28'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,
